Transimmunization for cutaneous T cell lymphoma: A phase I study

References

• Girardi M, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: Yesterday, today, and tomorrow. Hematol Oncol Clin North Am, M Demierre, 2003; 17: 1391–1403
   Google Scholar
• Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New Engl J Med 1987; 6: 297–303
   Web of Science ®Google Scholar
• Duvic M, Hester J P, Lemak N A. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573–579
   PubMed Web of Science ®Google Scholar
• Suchin K R, Cucchiara A J, Gottleib S L, Wolfe J T, DeNardo B J, Macey W H, Bromley P G, Vittorio C C, Rook A H. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: A 14-year experience at a single institution. Arch Dermatol 2002; 138: 1054–1060
   PubMed Web of Science ®Google Scholar
• Gottlieb S L, Wolfe J T, Fox F E, DeNardo B J, Macey W H, Bromley P G, Lessin S R, Rook A H. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946–957
   PubMed Web of Science ®Google Scholar
• Zic J A. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337–346
   PubMedGoogle Scholar
• Coyle T S, Nam T K, Camouse M M, Stevens S R, Baron E D. Steroid-sparing effect of extracorporeal photopheresis in the treatment of graft-vs-host disease. Arch Dermatol 2004; 140: 763–764
   PubMed Web of Science ®Google Scholar
• Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gurman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apheresis Sci 2004; 30: 185–187
   PubMed Web of Science ®Google Scholar
• Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transpl 2003; 31: 459–465
   PubMed Web of Science ®Google Scholar
• Greinix H T, Volc-Platzer B, Kalhs P, Fischer G, Rosenmayr A, Keil F, Honigsmann H, Knobler R M. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 2000; 96: 2426–2431
   PubMed Web of Science ®Google Scholar
• Foss F M. Extracorporeal photopheresis in the treatment of graft-vs-host disease. J Cutan Med Surg 2003; 7(suppl.)13–17
   PubMedGoogle Scholar
• Berger C L, Xu A L, Hanlon D, Lee C, Schechner J, Glusac E, Christensen I, Snyder E, Holloway V, Tigelaar R, Edelson R L. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001; 4: 438–447
   Web of Science ®Google Scholar
• Berger C L, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann NY Acad Sci 2001; 941: 106–122
   PubMed Web of Science ®Google Scholar
• Winter D, Fiebiger E, Meraner P, Auer H, Brna C, Strohal R, Trautinger F, Knobler R, Fischer G F, Stingl G, Maurer D. Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 2003; 171: 2714–2724
   PubMed Web of Science ®Google Scholar
• Usener D, Schadendorf D, Koch J, Dubel S, Eichmuller S. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J Invest Dermatol 2003; 121: 198–206
   PubMed Web of Science ®Google Scholar
• Haffner A C, Tassis A, Zepter K, Storz M, Tureci O, Burg G, Nestle F O. Expression of cancer/testis antigens in cutaneous T cell lymphomas. Int J Cancer 2003; 97: 668–670
   Web of Science ®Google Scholar
• Berger C L, Hanlon D, Kanada D, Girardi M, Edelson R L. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 2003; 3: 205–216
   Google Scholar
• Girardi M, Herreid P, Tigelaar R E. Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. J Invest Dermatol 1995; 104: 177–182
   PubMed Web of Science ®Google Scholar
• Maeda A, Schwarz A, Kernebeck K, Gross N, Aragane Y, Peritt D, Schwarz T. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005; 174: 5968–5976
   PubMed Web of Science ®Google Scholar
• Edelson R L. Transimmunization: The science catches up to the clinical success. Transfus Apheresis Sci 2002; 3: 177–180
   Web of Science ®Google Scholar
• Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apheresis Sci 2002; 3: 181–190
   Web of Science ®Google Scholar
• [Anonymous]. Bioresearch Monitoring Good Laboratory Practice Compliance Program 7348.808 (Nonclinical Laboratories) [Internet]. Food and Drug Administration web site. 2001, Available from: http://www.fda.gov/ora/compliance_ref/bimo/7348_808/default.htm
   Google Scholar
• Chen Z, Agostinelli A, Wilson L D, Nath R. Matching the dosimetry characteristics of a dual-field Stanford technique to a customized single-field Stanford technique for total skin electron therapy. Int J Rad Oncol 2004; 59: 872–885
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 3.0. 2003, Publish Date: March 28
   Google Scholar
• Duvic M, Martin A G, Kim Y, Olsen E, Wood G S, Crowley C A, Yocum R C. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581–593
   PubMed Web of Science ®Google Scholar
• Kung P C, Berger C L, Goldstein G, LoGerfo P, Edelson R L. Cutaneous T cell lymphoma: Characterization by monoclonal antibodies. Blood 1982; 57: 261–266
   Web of Science ®Google Scholar
• Glusac E J. Criterion by criterion, mycosis fungoides. Am J Dermatopathol 2003; 25: 264–269
   PubMed Web of Science ®Google Scholar
• Lamberg S I, Bunn P A, Jr. Proceedings of the Workshop on Cutaneous T-Cell Lymphomas (Mycosis Fungoides and Sezary Syndrome). Introduction. Cancer Treat Rep 1979; 63: 561–564
   PubMedGoogle Scholar
• Vonderheid E C, Bernengo M G, Burg G, Duvic M, Heald P, Laroche L, Olsen E, Pittelkow M, Russell-Jones R, Takigawa M, Willemze R. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 1: 95–106
   Web of Science ®Google Scholar
• Umeh O C, Kubak B M, Pegues D A, Leibowitz M R, Froch L. Corynebacterium jeikeium sepsis after 8-methoxypsolaren photopheresis for cutaneous T-cell lymphoma. Diagn Microbiol Infect Dis 2004; 50: 71–72
   PubMed Web of Science ®Google Scholar
• Wilson L D, Jones G W, Kim D, Rosenthal D, Christensen I R, Edelson R L, Heald P W, Kacinski B M. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol 2000; 43: 54–60
   PubMed Web of Science ®Google Scholar
• Teitz-Tennenbaum S, Li Q, Rynkiewicz S, Ito F, Davis M A, McGinn C J, Chang A E. Radiotherapy potentiates the therapeutic efficacy of intratumoral dendritic cell administration. Cancer Res 2003; 63: 8466–8475
   PubMed Web of Science ®Google Scholar
• Joo H G, Fleming T P, Tanaka Y, Dunn T J, Linehan D C, Goedegebuure P S, Eberlein T J. Human dendritic cells induce tumor-specific apoptosis by soluble factors. Int J Cancer 2002; 102: 20–28
   PubMed Web of Science ®Google Scholar